连网型糖尿病照护：创新与成长机会

连续血糖监测、人工胰臟系统和新型胰岛素配方改变了糖尿病管理的未来

人们越来越偏好使用穿戴式 CGM 来进行糖尿病自我评估，以取代指尖血糖值测量，尤其是第 1 型糖尿病 (T1D) 患者。目前，HbA1c 和 TIR 是糖尿病监测应用的首选生物标记。新的饮食/健身追踪应用程式可以支持您的整体健康，并帮助预防与文明病，例如糖尿病。先进人工智慧 (AI) 的使用透过提供对生理标记的预测见解（包括预测血糖值）来实现这些应用程式的预测能力。 2 型糖尿病 (T2D) 的传统处方药包括口服药物。儘管如此，胰岛素用于 T2D 治疗的使用仍在增加，特别是对于口服药物无法控制血糖值的患者。由于胰岛素输送平台的不断进步，胰岛素仍然是 T1D 患者的主要治疗方法。

混合封闭回路型系统或人工胰腺正在迅速成为 T1D 最佳管理的首选治疗选择。这些系统通常由复杂的演算法组成，促进 CGM、胰岛素帮浦以及监测和输送平台之间的串扰，以持续管理血糖值。越来越多地使用连接到智慧型手机应用程式的可穿戴监测设备，可以实现基于应用程式的个人化建议和可操作的预测见解，以改善糖尿病管理，推动数位疗法的发展。这项研究提供了连续血糖监测、胰岛素输送技术和人工胰臟进展的见解。我们也分析了将塑造全球糖尿病照护未来的资金筹措、新兴数位糖尿病照护技术以及合作关係。

目录

改变糖尿病照护产业

• 为什么成长如此困难？
• The Strategic Imperative 8（TM）
• 关键策略要务对连网型糖尿病护理产业的影响
• 成长机会推动Growth Pipeline Engine（TM）
• 调查方法

成长机会分析

• 糖尿病盛行率和相关健康风险概述
• 数位化糖尿病照护简介
• 分析范围
• 分割

成长发电机

• 生长促进因子
• 成长抑制因素

血糖监测技术

• 可穿戴 CGM 概述
• CGM 景观简介
• CGM 及相关应用程式分析
• 新 CGM 创新
• 要点与展望

HCL胰岛素输送系统

• HCL 胰岛素输送系统概述
• 人工胰臟情况简介
• 人工胰臟系统及相关应用分析
• HCL 领域的新创新
• 要点与展望

胰岛素输送技术

• 胰岛素输送技术概述
• 胰岛素输送竞争格局概况
• 最近/即将到来的胰岛素输送创新
• 主要观点及展望

资金筹措、合作伙伴关係和收购

• 资金筹措分析
• 主要合作伙伴和收购
• 糖尿病照护 - 观点

成长机会宇宙

• 成长机会 1：非侵入性连网型血糖感测器
• 成长机会2：小型穿戴式人工胰腺
• 增长机会3：口服胰岛素

下一步

Continuous Glucose Monitoring, Artificial Pancreas Systems, and Novel Insulin Delivery Formulations to Transform the Future of Diabetes Management

The preference for diabetes self-assessment using wearable CGMs instead of finger-stick blood sugar testing is increasing, especially in type 1 diabetics (T1D). HbA1c and time-in-range are currently the preferred biomarkers for diabetes monitoring applications. Emerging diet and fitness tracking apps help support general well-being and prevent the onset of lifestyle diseases such as diabetes. The use of advanced artificial intelligence (AI) has enabled the predictive capabilities of these apps by providing predictive insights on physiological markers, including the prediction of blood glucose levels. Conventional prescription medications for type 2 diabetes (T2D) comprise oral drugs. Still, there is a rising use of insulin for T2D management, especially for patients who are unable to manage blood sugar levels with oral medicines. Insulin continues to be a mainstay for treating T1D patients, with continuous advances in insulin delivery platforms.

Hybrid closed-loop systems or artificial pancreas are fast emerging as a preferred treatment option for optimally managing T1D. These systems typically comprise a CGM, an insulin pump, and an advanced algorithm that facilitates cross talk between the monitoring and delivery platforms for managing blood sugar levels continuously. The rising use of wearable monitoring devices connected through smartphone apps has enabled several app-based personalized recommendations and actionable predictive insights for improved diabetes management, leading to digital therapeutics development. This research provides insights into advancements in CGMs, insulin delivery technologies, and artificial pancreas. The study also analyzes funding, emerging digital diabetes care technologies, and partnerships shaping the future of global diabetes care.

The study answers the following questions: What are the key technological advancements in CGM devices and insulin delivery platforms? Who are the key innovators across device-based diabetes care platforms? How are funding and partnership trends likely to impact the diabetes care device industry? What are the emerging trends for digital diabetes care? What are the growth opportunities for digital diabetes management?

Table of Contents

Transformation in the Diabetes Care Sector

• Why Is It Increasingly Difficult to Grow?
• The Strategic Imperative 8™
• The Impact of the Top 3 Strategic Imperatives on the Connected Diabetes Care Industry
• Growth Opportunities Fuel the Growth Pipeline Engine™
• Research Methodology

Growth Opportunity Analysis

• Overview of Diabetes Prevalence and Associated Health Risks
• Snapshot of Digital Diabetes Care
• Scope of Analysis
• Segmentation

Growth Generator

• Growth Drivers
• Growth Restraints

Glucose Monitoring Technologies

• Overview of Wearable CGMs
• Snapshot of the CGM Landscape
• Analysis of CGMs and Related Apps
• Emerging CGM Innovations
• Key Takeaways and Outlook

HCL Insulin Delivery Systems

• Overview of HCL Insulin Delivery Systems
• Snapshot of the Artificial Pancreas Landscape
• Analysis of Artificial Pancreas Systems and Related Apps
• Emerging Innovations Across the HCL Landscape
• Key Takeaways and Outlook

Insulin Delivery Technologies

• Overview of Insulin Delivery Technologies
• Snapshot of the Competitive Landscape for Insulin Delivery
• Recent and Upcoming Insulin Delivery Innovations
• Key Takeaways and Outlook

Funding, Partnerships & Acquisitions

• Funding Analysis
• Key Partnerships and Acquisitions
• Diabetes Care-Outlook

Growth Opportunity Universe

• Growth Opportunity 1: Noninvasive Connected Glucose Sensors
• Growth Opportunity 2: Miniaturized Wearable Artificial Pancreas
• Growth Opportunity 3: Oral Insulin

Next Steps

• Benefits and Impacts of Growth Opportunities
• Next Steps
• Take the Next Step
• Legal Disclaimer